161. Familial benign chronic pemphigus Clinical trials / Disease details
Clinical trials : 5 / Drugs : 9 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 24
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05007223 (ClinicalTrials.gov) | May 8, 2020 | 5/8/2021 | Skin Microbiome Profile in Hailey-Hailey Disease | Characterization and Analysis of the Skin Microbiome in Hailey-Hailey Disease | Hailey-Hailey Disease | Drug: Doxycycline | Gangnam Severance Hospital | NULL | Completed | 19 Years | N/A | All | 18 | Korea, Republic of | |
| 2 | EUCTR2018-000373-80-FR (EUCTR) | 24/05/2018 | 13/03/2018 | A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease | A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease - DERM-101 | Darier’s Disease or Hailey-Hailey Disease MedDRA version: 20.0;Level: LLT;Classification code 10011860;Term: Darier's disease;System Organ Class: 100000004850 MedDRA version: 20.1;Classification code 10019029;Term: Hailey-Hailey disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: LX3305 250 mg capsule Product Code: LX3305 INN or Proposed INN: None Other descriptive name: (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime | Dermecular Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 1;Phase 2 | France | ||
| 3 | NCT02782702 (ClinicalTrials.gov) | September 2015 | 20/5/2016 | Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. | Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. Toxin Hailey Darier | Hailey-Hailey Disease;Darier Disease | Drug: Botulism Toxin Treatment | University Hospital, Toulouse | NULL | Completed | 18 Years | N/A | All | 30 | Phase 1 | NULL |
| 4 | EUCTR2013-004562-33-IT (EUCTR) | 17/12/2013 | 18/11/2013 | PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTS | PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTS | SYMPTOMATIC HHD PATIENTS MedDRA version: 16.1;Level: LLT;Classification code 10019029;Term: Hailey-Hailey disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: SCENESSE Product Name: SCENESSE | ISTITUTI FISIOTERAPICI OSPITALIERI | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 10 | Phase 2 | Italy | ||
| 5 | JPRN-UMIN000010191 | 2013/04/01 | 01/04/2013 | The examination of the clinical response of celecoxib in Darier's disease and Hailey-Hailey disease | Drier's disease Hailey-Hailey disease | celecoxib | Juntendo university gradurate school of medicine | NULL | Pending | 20years-old | Not applicable | Male and Female | 10 | Not selected | Japan |